a deal with big pharma is just selling off the farm or part of it to then have enough cash to sell a drug or 3. So it’s not really the biggest catalyst. The biggest catalyst in my view is efficacy, ( say half) and then drug approval …. And then that validates the platform. Worth another 3x those 2 combined. It’s just a matter of who values what when, but 4BUS for4 4 drugs in clinic is not a stretch at all. That’s 60x our mcap as of today.
PYC timelines to revenue, page-9
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
